Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study
- PMID: 22493375
Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study
Erratum in
- Anticancer Res. 2013 Nov;33(11):5211
Abstract
Background: Metastases to the liver receive most of their blood supply from the arterial route, therefore for patients with hepatic metastases from large bowel cancer, hepatic arterial infusion adopting drug-eluting beads preloaded with irinotecan (DEBIRI) may offer a chance of cure.
Patients and methods: In a multi-institutional study, 74 patients were randomly assigned to receive DEBIRI (36) versus systemic irinotecan, fluorouracil and leucovorin (FOLFIRI, 38). The primary end-point was survival; secondary end points were response, recurrence, toxicity, quality of life, cost and influence of molecular markers.
Results: At 50 months, overall survival was significantly longer for patients treated with DEBIRI than for those treated with FOLFIRI (p=0.031, log-rank). Median survival was 22 (95% Confidence Interval CI=21-23) months, for DEBIRI and 15 (95% CI=12-18) months for FOLFIRI. Progression-free survival was 7 (95% CI=3-11) months in the DEBIRI group compared to 4 (95% CI=3-5) months in the FOLFIRI group and the difference between groups was statistically significant (p=0.006, log-rank). Extrahepatic progression had occurred in all patients by the end of the study, at a median time of 13 (95% CI=10-16) months in the DEBIRI group compared to 9 (95% CI 5-13) months in the FOLFIRI group. A statistically significant difference between groups was not observed (p=0.064, log-rank).The median time for duration of improvement to quality of life was 8 (95% CI=3-13) months in the DEBIRI group and 3 (95% CI=2-4) months in the FOLFIRI group. The difference in duration of improvement was statistically significant (p=0.00002, log-rank).
Conclusion: This study showed a statistically significant difference between DEBIRI and FOLFIRI for overall survival (7 months), progression-free survival (3 months) and quality of life (5 months). In addition, a clinically significant improvement in time to extrahepatic progression (4 months) was observed for DEBIRI, a reversal of the expectation for a regional treatment. This suggests a benefit of DEBIRI treatment over standard chemotherapy and serves to establish the expected difference between these two treatment options for planning future large randomized studies.
Similar articles
-
Efficacy and Toxicity of Hepatic Intra-Arterial Drug-Eluting (Irinotecan) Bead (DEBIRI) Therapy in Irinotecan-Refractory Unresectable Colorectal Liver Metastases.World J Surg. 2016 May;40(5):1178-90. doi: 10.1007/s00268-015-3386-9. World J Surg. 2016. PMID: 26711640
-
Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study.Ann Surg Oncol. 2011 Jan;18(1):192-8. doi: 10.1245/s10434-010-1288-5. Epub 2010 Aug 26. Ann Surg Oncol. 2011. PMID: 20740319
-
Concomitant capecitabine with hepatic delivery of drug eluting beads in metastatic colorectal cancer.Anticancer Res. 2014 Dec;34(12):7239-45. Anticancer Res. 2014. PMID: 25503155
-
Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: systematic review.J Vasc Interv Radiol. 2013 Aug;24(8):1209-17. doi: 10.1016/j.jvir.2013.05.055. J Vasc Interv Radiol. 2013. PMID: 23885916
-
Intra-arterial therapies for colorectal cancer liver metastases (radioembolization excluded).Bull Cancer. 2017 May;104(5):402-406. doi: 10.1016/j.bulcan.2016.10.025. Epub 2016 Dec 16. Bull Cancer. 2017. PMID: 27993355 Review.
Cited by
-
Role of Transhepatic Arterial Radioembolization in Metastatic Colorectal Cancer.Cardiovasc Intervent Radiol. 2022 Nov;45(11):1579-1589. doi: 10.1007/s00270-022-03268-y. Epub 2022 Sep 14. Cardiovasc Intervent Radiol. 2022. PMID: 36104632 Review.
-
Investigation of the mechanisms governing doxorubicin and irinotecan release from drug-eluting beads: mathematical modeling and experimental verification.J Mater Sci Mater Med. 2013 Oct;24(10):2359-70. doi: 10.1007/s10856-013-4992-4. J Mater Sci Mater Med. 2013. PMID: 23797828
-
Chemoembolization Alone or Associated With Bevacizumab for Therapy of Colorectal Cancer Metastases: Preliminary Results of a Randomized Study.In Vivo. 2020 Mar-Apr;34(2):683-686. doi: 10.21873/invivo.11824. In Vivo. 2020. PMID: 32111770 Free PMC article. Clinical Trial.
-
Efficacy and Toxicity of Hepatic Intra-Arterial Drug-Eluting (Irinotecan) Bead (DEBIRI) Therapy in Irinotecan-Refractory Unresectable Colorectal Liver Metastases.World J Surg. 2016 May;40(5):1178-90. doi: 10.1007/s00268-015-3386-9. World J Surg. 2016. PMID: 26711640
-
Complications Following Irinotecan-Loaded Microsphere Chemoembolization of Colorectal Metastatic Liver Lesions Associated with Hepatic-Artery Branch Temporary Stasis.Curr Oncol. 2021 Jun 20;28(3):2296-2307. doi: 10.3390/curroncol28030211. Curr Oncol. 2021. PMID: 34203031 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical